{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:15:52Z","timestamp":1789096552992,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T00:00:00Z","timestamp":1515110400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40261-017-0617-x","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T21:55:24Z","timestamp":1515102924000},"page":"367-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Paola","family":"Bozzatello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-8000","authenticated-orcid":false,"given":"Silvio","family":"Bellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"key":"617_CR1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/jcm5080067","volume":"5","author":"P Bozzatello","year":"2016","unstructured":"Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5:67.","journal-title":"J Clin Med."},{"key":"617_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-3-319-28383-8_13","volume":"12","author":"R Grant","year":"2016","unstructured":"Grant R, Guest J. Role of omega-3 PUFAs in neurobiological health. Adv Neurobiol. 2016;12:247\u201374.","journal-title":"Adv Neurobiol."},{"issue":"2","key":"617_CR3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1567-5688(13)70005-9","volume":"14","author":"M Casula","year":"2013","unstructured":"Casula M, Soranna D, Catapano AL, Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl. 2013;14(2):243\u201351.","journal-title":"Atheroscler Suppl."},{"issue":"8","key":"617_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/jcm5080069","volume":"5","author":"G Berger","year":"2016","unstructured":"Berger G, Bozzatello P, et al. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5(8):69. https:\/\/doi.org\/10.3390\/jcm5080069.","journal-title":"J Clin Med."},{"issue":"2","key":"617_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bdi.12373","volume":"18","author":"JD Rosenblat","year":"2016","unstructured":"Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18(2):89\u2013101.","journal-title":"Bipolar Disord"},{"issue":"1\u20133","key":"617_CR6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.psychres.2007.01.004","volume":"157","author":"L Buydens-Branchey","year":"2008","unstructured":"Buydens-Branchey L, Branchey M. Long chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. Psychiatry Res. 2008;157(1\u20133):95\u2013104.","journal-title":"Psychiatry Res"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1038\/ncomms8934","volume":"6","author":"GP Amminger","year":"2015","unstructured":"Amminger GP, Sch\u00e4fer MR, Schlogelhofer M, Klier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934. https:\/\/doi.org\/10.1038\/ncomms8934.","journal-title":"Nat Commun."},{"issue":"2","key":"617_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0269881113510072","volume":"28","author":"S Bellino","year":"2014","unstructured":"Bellino S, Bozzatello P, Rocca G, Bogetto F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol. 2014;28(2):125\u201332.","journal-title":"J Psychopharmacol."},{"key":"617_CR9","volume-title":"Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR)","author":"American Psychiatric Association (APA)","year":"2000","unstructured":"American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR). 4th ed. Washington, DC: APA; 2000.","edition":"4"},{"key":"617_CR10","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)","author":"MB First","year":"1997","unstructured":"First MB, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Washington, DC: American Psychiatric Press; 1997."},{"key":"617_CR11","volume-title":"Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)","author":"MB First","year":"1997","unstructured":"First MB, Gibbon M, Spitzer RL. Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington, DC: American Psychiatric Press; 1997."},{"key":"617_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1521\/pedi.17.1.45.24053","volume":"17","author":"A Arntz","year":"2003","unstructured":"Arntz A, Van den Hoorn M, Cornelis J, Verheul R, Van den Bosch WM, De Bie A. Reliability and validity of the borderline personality disorder severity index. J Personal Disord. 2003;17:45\u201359.","journal-title":"J Personal Disord."},{"key":"617_CR13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2466\/pr0.1965.16.2.547","volume":"16","author":"ES Barratt","year":"1965","unstructured":"Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep. 1965;16:547\u201354.","journal-title":"Psychol Rep"},{"key":"617_CR14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/(SICI)1097-4679(199811)54:7<973::AID-JCLP11>3.0.CO;2-H","volume":"54","author":"RA Sansone","year":"1998","unstructured":"Sansone RA, Wiederman MW, Sansone LA. The Self-harm Inventory (SHI): development of a scale for identifying self-destructive behaviors and borderline personality disorder. J Clin Psychol. 1998;54:973\u201383.","journal-title":"J Clin Psychol"},{"key":"617_CR15","doi-asserted-by":"publisher","unstructured":"Stoffers J, V\u00f6llm BA, R\u00fccker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. https:\/\/doi.org\/10.1002\/14651858.CD005653.pub2.","DOI":"10.1002\/14651858.CD005653.pub2"},{"issue":"4","key":"617_CR16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI118507","volume":"97","author":"T Hamazaki","year":"1996","unstructured":"Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, et al. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest. 1996;97(4):1129\u201333.","journal-title":"J Clin Invest."},{"issue":"1","key":"617_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10284150290007119","volume":"5","author":"T Hamazaki","year":"2002","unstructured":"Hamazaki T, Thienprasert A, Kheovichai K. The effect of docosahexaenoic acid on aggression in elderly Thai subjects\u2014a placebo-controlled double-blind study. Nutr Neurosci. 2002;5(1):37\u201341.","journal-title":"Nutr Neurosci."},{"issue":"2","key":"617_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09540260600582009","volume":"18","author":"MR Garland","year":"2006","unstructured":"Garland MR, Hallahan B. Essential fatty acids and their role in conditions characterised by impulsivity. Int Rev Psychiat. 2006;18(2):99\u2013105.","journal-title":"Int Rev Psychiat."},{"issue":"6","key":"617_CR19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1521\/pedi.2010.24.6.694","volume":"24","author":"JG Gunderson","year":"2010","unstructured":"Gunderson JG. Revising the borderline diagnosis for DSM-V: an alternative proposal. J Pers Disord. 2010;24(6):694\u2013708.","journal-title":"J Pers Disord"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0617-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T07:32:51Z","timestamp":1521185571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0617-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0617-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,5]]}}}